A Phase 2/3 Postexposure Prophylaxis Study of PF-07321332/Ritonavir in Household Contacts of a Patient with COVID-19. (Pfizer 1006)


To compare the efficacy of 5-day and 10-day regimens of PF-07321332/ritonavir versus placebo in preventing symptomatic RT-PCR+ SARS-CoV-2 infection in adult participants who are household contacts of a patient recently diagnosed with symptomatic Covid 19.



1.  At least 18 years old.

2.  No current symptoms of Covid-19/

You cannot:

Have received Covid vaccine within 6 months prior to screening.

Have a history of Covid-19 within 6 months of screening.

 Have fever or any other symptoms of Covid-19

 Have liver or kidney disease.

 Have any other current infection.

 Have cancer.


Study process:

1. Nasopharyngeal swabs and lab drawn at select visits.

2. Patient stipend.

3. No cost of drug to patient or insurance.

4. Free Covid-19 testing.

Interested in more information on clinical research? Contact WK Health System Clinical Research Department 318-212-8130 or ckay@wkhs.com

Interested in more information? Contact Us:

Joseph Bocchini, M.D., Principal Investigator

IRB: Advarra Institutional Review Board
IRB Number:
Trial Type: Drug
Sponsor: Pfizer